Tanaka Rina, Sasaki Akinori, Sano Shoko, Mizokami Ken
{"title":"Olaparib for Simultaneous Occurrence of Breast Cancer and Ovarian Cancer with BRCA1","authors":"Tanaka Rina, Sasaki Akinori, Sano Shoko, Mizokami Ken","doi":"10.36959/739/528","DOIUrl":"https://doi.org/10.36959/739/528","url":null,"abstract":"","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69788528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Broecker Justine S, Liu Yuan S, Dewey Betsey, Styblo Toncred, Gillespie Theresa S
{"title":"Patterns of Care and Predictors of Survival among DCIS Patients: An NCDB Analysis","authors":"Broecker Justine S, Liu Yuan S, Dewey Betsey, Styblo Toncred, Gillespie Theresa S","doi":"10.36959/739/526","DOIUrl":"https://doi.org/10.36959/739/526","url":null,"abstract":"","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46428482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gagan Gupta, Caroline Dasom Lee, Mary L Guye, Robert E Van Sciver, Michael P Lee, Alex C Lafever, Anthony Pang, Angela M Tang-Tan, Janet S Winston, Billur Samli, Rick J Jansen, Richard A Hoefer, Amy H Tang
Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical prognostic tools evaluate four clinicopathological factors: Tumor size, LN status, pathological stage, and tumor molecular subtype. However, many similarly treated patients with identical residual cancer burden (RCB) following NACT experience distinctly different tumor relapse rates, clinical outcomes and survival. This problem is particularly apparent for incomplete responders with a high-risk RCB classification following NACT. Therefore, there is a pressing need to identify new prognostic and predictive biomarkers, and develop novel curative therapies to augment current standard of care (SOC) treatment regimens to save more lives. Here, we will discuss these unmet needs and clinical challenges that stand in the way of precision medicine and personalized cancer therapy.
{"title":"Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.","authors":"Gagan Gupta, Caroline Dasom Lee, Mary L Guye, Robert E Van Sciver, Michael P Lee, Alex C Lafever, Anthony Pang, Angela M Tang-Tan, Janet S Winston, Billur Samli, Rick J Jansen, Richard A Hoefer, Amy H Tang","doi":"10.36959/739/525","DOIUrl":"https://doi.org/10.36959/739/525","url":null,"abstract":"<p><p>Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical prognostic tools evaluate four clinicopathological factors: Tumor size, LN status, pathological stage, and tumor molecular subtype. However, many similarly treated patients with identical residual cancer burden (RCB) following NACT experience distinctly different tumor relapse rates, clinical outcomes and survival. This problem is particularly apparent for incomplete responders with a high-risk RCB classification following NACT. Therefore, there is a pressing need to identify new prognostic and predictive biomarkers, and develop novel curative therapies to augment current standard of care (SOC) treatment regimens to save more lives. Here, we will discuss these unmet needs and clinical challenges that stand in the way of precision medicine and personalized cancer therapy.</p>","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"4 1","pages":"48-57"},"PeriodicalIF":0.0,"publicationDate":"2020-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38049628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kitada Masahiro, Yasuda Shunsuke, A. Masahiro, Yoshida Nana, Okazaki Satoshi, Ishibashi Kei
Male breast cancer is rare, accounting for approximately 0.5-1.0% of all cases and is often a hormone-dependent luminal type. The percentage of hormone-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer cases is very small in male patients (0.6-1.2%), and the prognosis is generally poor.
{"title":"Difficult-to-Diagnose Hormone-Negative, Human Epidermal Growth Factor Receptor 2-Positive Poorly-Differentiated Breast Cancer in a Male Patient","authors":"Kitada Masahiro, Yasuda Shunsuke, A. Masahiro, Yoshida Nana, Okazaki Satoshi, Ishibashi Kei","doi":"10.36959/739/524","DOIUrl":"https://doi.org/10.36959/739/524","url":null,"abstract":"Male breast cancer is rare, accounting for approximately 0.5-1.0% of all cases and is often a hormone-dependent luminal type. The percentage of hormone-negative, human epidermal growth factor receptor 2 (HER2)-positive breast cancer cases is very small in male patients (0.6-1.2%), and the prognosis is generally poor.","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42448438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
African American women have a greater number of aggressive cancer treatments and higher incidence of Breast Cancer-Related Lymphedema (BCRLE) than Caucasians. BCRLE cannot be cured and the treatment requires patients to make considerable lifestyle changes and maintain daily and lifelong care to decrease the swelling and prevent exacerbations.
{"title":"The Lived Experience of African American Women with Lymphedema","authors":"Collins-Bohler Deborah","doi":"10.36959/739/522","DOIUrl":"https://doi.org/10.36959/739/522","url":null,"abstract":"African American women have a greater number of aggressive cancer treatments and higher incidence of Breast Cancer-Related Lymphedema (BCRLE) than Caucasians. BCRLE cannot be cured and the treatment requires patients to make considerable lifestyle changes and maintain daily and lifelong care to decrease the swelling and prevent exacerbations.","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43158771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Salih, F. Calaud, K. Rasul, M. Elmistiri, N. Elhadi, Hafez Gazouani, S. Bujassoum
Background: Oncotype DX risk score, a clinically validated test that estimates the recurrence and predicts the likelihood of benefit from adjuvant chemotherapy in early ERPR positive, node-negative breast cancer, it is calculated based on characteristics of 21 genes that define the ER status, Her2 neu status, tumor proliferation, and tumor invasion. NCCN guidelines recommend adjuvant endocrine therapy for low RS (<18) and systemic adjuvant chemotherapy for high RS (>30), but no clear consensus about chemotherapy role in intermediate RS [18-30]. The aim of the study: Look for Oncotype Dx correlation, with clinicopathologic risk factors (age, tumor histology, tumor size, tumor grade, ER/PR status, tumor proliferation index) and chemotherapy. We did also evaluate how John Hopkins university recurrence score online tool can be utilized in filtering patient for Oncotype DX testing. Methods: Retrospective records review of approximately 54 patients who had Oncotype DX test during 2012-2017 in National Cancer Center–Qatar. Result: Of 54 patients studied 64.8% had low RS, 27.8% had intermediate RS, and 7.4% had high RS. Univariate analysis showed significant correlation with tumor grade (p<0.003), PR% status (cut-off 1%; p<0.016) and Ki67% (cut-off 20%; p<0.001). There was no significant correlation with patient age, tumor histology or tumor size. In multivariate analysis, only Ki67% predicted the Oncotype DX RS (p<0.028). JHU recurrence score had a moderate association with Oncotype DX RS at strength of agreement 0.524 (Cohen Kappa) Adjuvant chemotherapy treatment correlated significantly with the Oncotype DX RS in both univariate analysis (p < 0.002) and multivariate analysis (p < 0.003) Conclusion: Oncotype RS correlates significantly with the tumor grade, Ki67%, PR status, and chemotherapy treatment. JHU recurrence score has reasonable utility in filtering patient for Oncotype DX testing.
{"title":"Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy. Retrospective study in early stage ER positive breast cancer","authors":"F. Salih, F. Calaud, K. Rasul, M. Elmistiri, N. Elhadi, Hafez Gazouani, S. Bujassoum","doi":"10.33582/2640-8198/1005","DOIUrl":"https://doi.org/10.33582/2640-8198/1005","url":null,"abstract":"Background: Oncotype DX risk score, a clinically validated test that estimates the recurrence and predicts the likelihood of benefit from adjuvant chemotherapy in early ERPR positive, node-negative breast cancer, it is calculated based on characteristics of 21 genes that define the ER status, Her2 neu status, tumor proliferation, and tumor invasion. NCCN guidelines recommend adjuvant endocrine therapy for low RS (<18) and systemic adjuvant chemotherapy for high RS (>30), but no clear consensus about chemotherapy role in intermediate RS [18-30]. The aim of the study: Look for Oncotype Dx correlation, with clinicopathologic risk factors (age, tumor histology, tumor size, tumor grade, ER/PR status, tumor proliferation index) and chemotherapy. We did also evaluate how John Hopkins university recurrence score online tool can be utilized in filtering patient for Oncotype DX testing. Methods: Retrospective records review of approximately 54 patients who had Oncotype DX test during 2012-2017 in National Cancer Center–Qatar. Result: Of 54 patients studied 64.8% had low RS, 27.8% had intermediate RS, and 7.4% had high RS. Univariate analysis showed significant correlation with tumor grade (p<0.003), PR% status (cut-off 1%; p<0.016) and Ki67% (cut-off 20%; p<0.001). There was no significant correlation with patient age, tumor histology or tumor size. In multivariate analysis, only Ki67% predicted the Oncotype DX RS (p<0.028). JHU recurrence score had a moderate association with Oncotype DX RS at strength of agreement 0.524 (Cohen Kappa) Adjuvant chemotherapy treatment correlated significantly with the Oncotype DX RS in both univariate analysis (p < 0.002) and multivariate analysis (p < 0.003) Conclusion: Oncotype RS correlates significantly with the tumor grade, Ki67%, PR status, and chemotherapy treatment. JHU recurrence score has reasonable utility in filtering patient for Oncotype DX testing.","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73474664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pro-necroptotic agents in cancer therapy","authors":"A. El-Sharkawy, A. Malki","doi":"10.33582/2640-8198/1004","DOIUrl":"https://doi.org/10.33582/2640-8198/1004","url":null,"abstract":"","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88746299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Roner, C. Carraher, Kimberly R. Shahi, Alisha Moric-Johnson, Lindsey C. Miller, P. Slawek, Francesca Mosca
{"title":"Control of breast cancer using metal-containing polymers based on cell line results","authors":"M. Roner, C. Carraher, Kimberly R. Shahi, Alisha Moric-Johnson, Lindsey C. Miller, P. Slawek, Francesca Mosca","doi":"10.33582/2640-8198/1003","DOIUrl":"https://doi.org/10.33582/2640-8198/1003","url":null,"abstract":"","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"1999 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78110503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting","authors":"Quintyne Ki, B Woulfe, Coffey Jc, Gupta Rk","doi":"10.33582/2640-8198/1002","DOIUrl":"https://doi.org/10.33582/2640-8198/1002","url":null,"abstract":"","PeriodicalId":92983,"journal":{"name":"Annals of breast cancer and therapy","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79120127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号